https://scholars.lib.ntu.edu.tw/handle/123456789/548829
標題: | Burden of asthma and COPD overlap (ACO) in Taiwan: A nationwide population-based study | 作者: | Shantakumar S. Pwu R.-F. D'Silva L. Wurst K. YAO-WEN KUO Yang Y.-Y. Juan Y.-C. KIN-WEI CHAN |
公開日期: | 2018 | 出版社: | BioMed Central Ltd. | 卷: | 18 | 期: | 1 | 來源出版物: | BMC Pulmonary Medicine | 摘要: | Background: Patients with symptoms of both asthma and chronic obstructive pulmonary disease (COPD) may be classified with the term asthma-COPD overlap (ACO). ACO is of considerable interest as it is currently poorly characterised and has been associated with worse health outcomes and higher healthcare costs compared with COPD or asthma alone. Patients with ACO in Asia remain poorly described, and there is limited information regarding their resource utilisation compared with patients with asthma or COPD only. This study investigated the characteristics, disease burden and medical resource utilisation of patients with ACO in Taiwan. Methods: This was a retrospective cohort study of patients identified from National Health Insurance (NHI) claims data in Taiwan in 2009-2011. Patients were classified into incident ACO, COPD or asthma cohorts according to International Classification of Disease, ninth revision, clinical modification codes in claims. Eligible patients were ?40 years of age with 12 months' continuous enrolment in the NHI programme pre- and post-index date (date of the first relevant medical claim). Results: Patients with ACO (N = 22,328) and COPD (N = 69,648) were older and more likely to be male than those with asthma (N = 50,293). Patients with ACO had more comorbidities and exacerbations, with higher medication use: short-acting β 2 -agonist prescriptions ranged from 30.4% of patients (asthma cohort) to 43.6% (ACO cohort), and inhaled corticosteroid/long-acting β 2 -agonist combination prescriptions ranged from 11.1% (COPD cohort) to 35.0% (ACO cohort) in the 12 months following index. Patients with ACO generally had the highest medication costs of any cohort (long-acting muscarinic antagonist costs ranged from $227/patient [asthma cohort] to $349/patient [ACO cohort]); they also experienced more respiratory-related hospital visits than patients with asthma or COPD (mean outpatient/inpatient visits per patient post-index: 9.1/1.9 [ACO cohort] vs 5.7/1.4 [asthma cohort] and 6.4/1.7 [COPD cohort]). Conclusions: Patients with ACO in Taiwan experience a greater disease burden with greater healthcare resource utilisation, and higher costs, than patients with asthma or COPD alone. ? 2018 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040981901&doi=10.1186%2fs12890-017-0571-7&partnerID=40&md5=0210d6964f9304caaf0a4bfe55bbf7fd https://scholars.lib.ntu.edu.tw/handle/123456789/548829 |
ISSN: | 1471-2466 | DOI: | 10.1186/s12890-017-0571-7 | SDG/關鍵字: | beta 2 adrenergic receptor stimulating agent; corticosteroid; corticosteroid; adult; aged; Article; asthma; asthma chronic obstructive lung disease overlap; asthma chronic obstructive lung disease overlap; chronic obstructive lung disease; cohort analysis; comorbidity; controlled study; disease burden; disease exacerbation; disease severity; drug cost; female; health care cost; health care utilization; hospital care; hospital patient; human; ICD-9; ICD-9-CM; incidence; lung disease; major clinical study; male; middle aged; national health insurance; outpatient; population research; retrospective study; Taiwan; age; ambulatory care; asthma; chronic obstructive lung disease; economics; health care planning; hospitalization; recurrent disease; sex factor; statistics and numerical data; very elderly; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Asthma; Drug Costs; Female; Health Resources; Hospitalization; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Sex Factors; Symptom Flare Up; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。